ImageneBio Inc
NASDAQ:IMABiotechnology
+$0.35 today
- Market cap
- $52.00M
- Beta
- 0.72
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.02
Volume 0.00M
Average 0.35M
Returns on capital
ImageneBio Inc management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.1%
avg -0.8%
ROIC
-33.4%
avg -58.6%
ROA
-29.6%
avg -48.5%
Analysis
ROA is currently the strongest return metric at -29.6% versus its period average of -48.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kristin Yarema | CEO & Director | USD 710.35K | 55 | 137.20K | 1.22% |
Benjamin Porter-Brown | Chief Medical Officer | USD 588.36K | 53 | 0 | <0.01% |
Kurinji Pandiyan | Chief Strategy & Operations Officer | — | — | — | — |
Matt Robbins | General Counsel | — | — | — | — |
Yanina Grant-Huerta | CFO, Principal Financial Officer & Principal Accounting Officer | — | 49 | 56.00K | 0.50% |
Renuka Sivendran | Chief Technical Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Oct 3, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$97,282.58
Sells
2
$17,334.00
Net Transaction Value
+$79,948.58
Net buying
Most Active
Lally Robert B
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 17, 26Jul 17, 2026 | Lally Robert B Direct | Sell | $8.1K$8,143.50 |
| Jul 16, 26Jul 16, 2026 | Lally Robert B Direct | Sell | $9.2K$9,190.50 |
| Apr 14, 26Apr 14, 2026 | Bonita David P Indirect | Buy | $384.7$384.69 |
| Apr 14, 26Apr 14, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $384.7$384.69 |
| Apr 14, 26Apr 14, 2026 | ORBIMED ADVISORS LLC Indirect | Buy | $336.6$336.60 |
| Apr 14, 26Apr 14, 2026 | Bonita David P Indirect | Buy | $336.6$336.60 |
| Dec 24, 25Dec 24, 2025 | SLATTERY JOSEPH P Direct | Buy | $95.8K$95,840.00 |
Summary
Insiders reported 5 buys worth $97,282.58 and 2 sells worth $17,334.00 over the last 12 months. That adds up to net buying of $79,948.58. Lally Robert B was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -62.9% | +91.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -62.9% over three years. Forward estimates point to Revenue at +91.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ImageneBio Inc compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IMA's management, answered from reported figures.
Who manages IMA?
ImageneBio Inc (IMA) lists 6 active executives. The top listed executive is Kurinji Pandiyan, Chief Strategy & Operations Officer.
Are IMA insiders buying or selling?
Recent insider activity shows net buying of $33.01M.
Continue the stock analysis
Jump to another research area for this company.